DISEASE SCANNER
Global Incurable Diseases Tracker
Thrombotic Thrombocytopenic Purpura (TTP)
Rare, life-threatening blood disorder causing blood clots in small blood vessels throughout the body. Characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ ischemia. Caused by ADAMTS13 deficiency or inhibitors.
10.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Complete blood count
- 2Peripheral blood smear (schistocytes)
- 3ADAMTS13 activity and inhibitor levels
- 4LDH level
- 5Reticulocyte count
- 6Coombs test
Prognosis
Without treatment, mortality exceeds 90%. With plasma exchange, survival improves to 80-90%. Caplacizumab further reduces mortality. Relapse occurs in 30-50% of autoimmune TTP. Long-term follow-up essential. Neurological and renal complications can persist. Early diagnosis and treatment critical.
Prevention
- No primary prevention
- Regular ADAMTS13 monitoring (remission)
- Genetic counseling (hereditary form)
- Avoiding triggers (known precipitants)
Research Status
Plasma exchange (plasmapheresis) is first-line treatment. Caplacizumab (anti-vWF nanobody) reduces mortality. Corticosteroids and rituximab for autoimmune TTP. Splenectomy for refractory cases. Recombinant ADAMTS13 in development.
Affected Countries
Sources
- https://www.hematology.org
- https://www.ncbi.nlm.nih.gov/books/NBK6614
- https://www.mayoclinic.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.